| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Endocrinology and Metabolism [A. S., G. R. M., T. Y.] and Department of Pathology [B. F. B., B. S., K. R. W.], San Antonio, Texas 78284-7877 and Rhône-Poulenc Rorer, Collegeville, Pennsylvania 19486 [M. C., R. B.]
Human breast cancer frequently metastasizes to the skeleton to cause osteolysis and subsequent pain, pathological fracture, and hypercalcemia. Because bone continuously releases growth factors stored in bone matrix by bone resorption during physiological remodeling and, thus, possibly provides a favorable microenvironment for metastatic breast cancer cells to proliferate, inhibitors of bone resorption used either prophylactically or in patients with established disease, therefore, would seem likely to be useful adjuvant therapy in patients with breast cancer. However, the parameters for monitoring progressive osteolytic bone disease in humans are imprecise. We examined the effects of the third generation bisphosphonate, risedronate, which is a specific inhibitor of osteoclastic bone resorption, in a bone metastasis model in nude mice in which intracardiac injection of the human breast cancer cell line MDA-231 leads to osteolytic bone metastases. Risedronate (4 µg/animal/day) was given s.c. to animals (a) after radiologically small but defined osteolytic metastases were observed; (b) simultaneously with MDA-231 cell inoculation through the entire experimental period; or (c) by short-term prophylactic administration before inoculation of MDA-231 cells. In all experiments, risedronate either slowed progression or inhibited the development of bone metastases assessed radiographically. Furthermore, mice treated continuously with risedronate showed significantly longer survival than did control mice. Histomorphometrical analysis revealed that osteoclast numbers were diminished at metastatic tumor sites. Unexpectedly, there was also a marked decrease in tumor burden in bone in risedronate-treated animals. In contrast, the growth of metastatic breast cancer in soft tissues surrounding bones was not affected by risedronate. Moreover, risedronate had no effects on the local growth of s.c. implanted MDA-231 breast cancers in nude mice or on MDA-231 cell proliferation in culture. These data demonstrate that risedronate decreases metastatic MDA-231 breast cancer burden selectively in bone, as well as suppresses progression of established osteolytic lesions and prevents the development of new osteolytic lesions; thus, the data suggest that inhibition of osteoclastic bone resorption may be a useful adjunctive therapy for the treatment of cancers that have colonized in bone.
1 This work was supported by National Cancer Institute Grants CA-40035 and CA-58183 (Specialized Programs of Research Excellence in Breast Cancer).
2 Present address: Department of Oral and Maxillofacial Surgery II, Okayama University School of Dentistry, Okayama 700, Japan.
3 To whom requests for reprints should be addressed, at the University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Endocrinology and Metabolism, 7703 Floyd Curl Drive, San Antonio, TX 78284-7877.
Received 2/13/95. Accepted 6/ 8/95.
This article has been cited by other articles:
|
|
 |
|
  A. A. El-Mabhouh, P. N. Nation, A. Kaddoura, and J. R. Mercer Unexpected Preferential Brain Metastases with a Human Breast Tumor Cell Line MDA-MB-231 in BALB/c Nude Mice Vet. Pathol., November 1, 2008; 45(6): 941 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ottewell, H. Monkkonen, M. Jones, D. V. Lefley, R. E. Coleman, and I. Holen Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer J Natl Cancer Inst, August 20, 2008; 100(16): 1167 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ottewell, B. Deux, H. Monkkonen, S. Cross, R. E. Coleman, P. Clezardin, and I. Holen Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo Clin. Cancer Res., July 15, 2008; 14(14): 4658 - 4666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Delaney, S. M. Fleetwood-Walker, L. A. Colvin, and M. Fallon Translational medicine: cancer pain mechanisms and management Br. J. Anaesth., July 1, 2008; 101(1): 87 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Melani, S. Sangaletti, F. M. Barazzetta, Z. Werb, and M. P. Colombo Amino-Biphosphonate Mediated MMP-9 Inhibition Breaks the Tumor-Bone Marrow Axis Responsible for Myeloid-Derived Suppressor Cell Expansion and Macrophage Infiltration in Tumor Stroma Cancer Res., December 1, 2007; 67(23): 11438 - 11446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Dvorak, T.-H. Chen, B. Orwoll, C. Garvey, W. Chang, D. D. Bikle, and D. M. Shoback Constitutive Activity of the Osteoblast Ca2+-Sensing Receptor Promotes Loss of Cancellous Bone Endocrinology, July 1, 2007; 148(7): 3156 - 3163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Hirbe, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, K. Trinkaus, A. Apicelli, and K. Weilbaecher Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner Blood, April 15, 2007; 109(8): 3424 - 3431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ohno, K. Kubo, H. Murooka, Y. Kobayashi, T. Nishitoba, M. Shibuya, T. Yoneda, and T. Isoe A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol. Cancer Ther., November 1, 2006; 5(11): 2634 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wakchoure, M. A. Merrell, W. Aldrich, T. Millender-Swain, K. W. Harris, P. Triozzi, and K. S. Selander Bisphosphonates Inhibit the Growth of Mesothelioma Cells In vitro and In vivo. Clin. Cancer Res., May 1, 2006; 12(9): 2862 - 2868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mystakidou, E. Katsouda, E. Parpa, E. Kouskouni, C. Chondros, M. L. Tsiatas, A. Galanos, and L. Vlahos A prospective randomized controlled clinical trial of zoledronic acid for bone metastases American Journal of Hospice and Palliative Medicine, January 1, 2006; 23(1): 41 - 50. [Abstract] [PDF]
|
|
|
|
|
|
K. Inoue, T. Karashima, S. Fukata, A. Nomura, C. Kawada, A. Kurabayashi, M. Furihata, Y. Ohtsuki, and T. Shuin Effect of Combination Therapy with a Novel Bisphosphonate, Minodronate (YM529), and Docetaxel on a Model of Bone Metastasis by Human Transitional Cell Carcinoma Clin. Cancer Res., September 15, 2005; 11(18): 6669 - 6677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. van der Pluijm, I. Que, B. Sijmons, J. T. Buijs, C. W.G.M. Lowik, A. Wetterwald, G. N. Thalmann, S. E. Papapoulos, and M. G. Cecchini Interference with the Microenvironmental Support Impairs the De novo Formation of Bone Metastases In vivo Cancer Res., September 1, 2005; 65(17): 7682 - 7690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schneider, L. M. Kalikin, A. C. Mattos, E. T. Keller, M. J. Allen, K. J. Pienta, and L. K. McCauley Bone Turnover Mediates Preferential Localization of Prostate Cancer in the Skeleton Endocrinology, April 1, 2005; 146(4): 1727 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hashimoto, K.-i. Morishige, K. Sawada, M. Tahara, R. Kawagishi, Y. Ikebuchi, M. Sakata, K. Tasaka, and Y. Murata Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model Cancer Res., January 15, 2005; 65(2): 540 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mori, N. Shimizu, M. Dallas, M. Niewolna, B. Story, P. J. Williams, G. R. Mundy, and T. Yoneda Anti-{alpha}4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis Blood, October 1, 2004; 104(7): 2149 - 2154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiraga, P. J. Williams, A. Ueda, D. Tamura, and T. Yoneda Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model Clin. Cancer Res., July 1, 2004; 10(13): 4559 - 4567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yano, H. Zhang, M. Hanibuchi, T. Miki, H. Goto, H. Uehara, and S. Sone Combined Therapy with a New Bisphosphonate, Minodronate (YM529), and Chemotherapy for Multiple Organ Metastases of Small Cell Lung Cancer Cells in Severe Combined Immunodeficient Mice Clin. Cancer Res., November 1, 2003; 9(14): 5380 - 5385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, N. S. Mitsiades, R. T. Bronson, D. Chauhan, N. Munshi, S. P. Treon, C. A. Maxwell, L. Pilarski, T. Hideshima, R. M. Hoffman, et al. Fluorescence Imaging of Multiple Myeloma Cells in a Clinically Relevant SCID/NOD in Vivo Model: Biologic and Clinical Implications Cancer Res., October 15, 2003; 63(20): 6689 - 6696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Santini, U. Vespasiani Gentilucci, B. Vincenzi, A. Picardi, F. Vasaturo, A. La Cesa, N. Onori, S. Scarpa, and G. Tonini The antineoplastic role of bisphosphonates: from basic research to clinical evidence Ann. Onc., October 1, 2003; 14(10): 1468 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Abrams, L. J. Murray, E. Pesenti, V. Walker Holway, T. Colombo, L. B. Lee, J. M. Cherrington, and N. K. Pryer Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer Mol. Cancer Ther., October 1, 2003; 2(10): 1011 - 1021. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. R. Mundy Endothelin-1 and osteoblastic metastasis PNAS, September 16, 2003; 100(19): 10588 - 10589. [Full Text] [PDF]
|
|
|
|
|
|
A. Myoui, R. Nishimura, P. J. Williams, T. Hiraga, D. Tamura, T. Michigami, G. R. Mundy, and T. Yoneda C-Src Tyrosine Kinase Activity Is Associated with Tumor Colonization in Bone and Lung in an Animal Model of Human Breast Cancer Metastasis Cancer Res., August 15, 2003; 63(16): 5028 - 5033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Corey, L. G. Brown, J. E. Quinn, M. Poot, M. P. Roudier, C. S. Higano, and R. L. Vessella Zoledronic Acid Exhibits Inhibitory Effects on Osteoblastic and Osteolytic Metastases of Prostate Cancer Clin. Cancer Res., January 1, 2003; 9(1): 295 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Mundy Bisphosphonates and Tumor Burden J. Clin. Oncol., August 1, 2002; 20(15): 3191 - 3192. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ishida, N. Fujita, R. Kitazawa, and T. Tsuruo Transforming Growth Factor-beta Induces Expression of Receptor Activator of NF-kappa B Ligand in Vascular Endothelial Cells Derived from Bone J. Biol. Chem., July 12, 2002; 277(29): 26217 - 26224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Winding, R. NicAmhlaoibh, H. Misander, P. Hoegh-Andersen, T. L. Andersen, C. Holst-Hansen, A.-M. Heegaard, N. T. Foged, N. Brunner, and J.-M. Delaisse Synthetic Matrix Metalloproteinase Inhibitors Inhibit Growth of Established Breast Cancer Osteolytic Lesions and Prolong Survival in Mice Clin. Cancer Res., June 1, 2002; 8(6): 1932 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Virtanen, H. K. Vaananen, P. L. Harkonen, and P. T. Lakkakorpi Alendronate Inhibits Invasion of PC-3 Prostate Cancer Cells by Affecting the Mevalonate Pathway Cancer Res., May 1, 2002; 62(9): 2708 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. M. Duivenvoorden, S. V. Popovic, S. Lhotak, E. Seidlitz, H. W. Hirte, R. G. Tozer, and G. Singh Doxycycline Decreases Tumor Burden in a Bone Metastasis Model of Human Breast Cancer Cancer Res., March 1, 2002; 62(6): 1588 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yi, P. J. Williams, M. Niewolna, Y. Wang, and T. Yoneda Tumor-derived Platelet-derived Growth Factor-BB Plays a Critical Role in Osteosclerotic Bone Metastasis in an Animal Model of Human Breast Cancer Cancer Res., February 1, 2002; 62(3): 917 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Brown HER-2/neu-Positive Breast Carcinoma: Molecular Concomitants by Proteomic Analysis and their Therapeutic Implications Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 12 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. van der Pluijm, B. Sijmons, H. Vloedgraven, C. van der Bent, J.-W. Drijfhout, J. Verheijen, P. Quax, M. Karperien, S. Papapoulos, and C. Lowik Urokinase-Receptor/Integrin Complexes Are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo Am. J. Pathol., September 1, 2001; 159(3): 971 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Das, L. Wang, A. Kamath, and J. F. Bukowski V{gamma}2V{delta}2 T-cell receptor-mediated recognition of aminobisphosphonates Blood, September 1, 2001; 98(5): 1616 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiraga, P. J. Williams, G. R. Mundy, and T. Yoneda The Bisphosphonate Ibandronate Promotes Apoptosis in MDA-MB-231 Human Breast Cancer Cells in Bone Metastases Cancer Res., June 1, 2001; 61(11): 4418 - 4424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Morony, C. Capparelli, I. Sarosi, D. L. Lacey, C. R. Dunstan, and P. J. Kostenuik Osteoprotegerin Inhibits Osteolysis and Decreases Skeletal Tumor Burden in Syngeneic and Nude Mouse Models of Experimental Bone Metastasis Cancer Res., June 1, 2001; 61(11): 4432 - 4436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crandall Risedronate: A Clinical Review Arch Intern Med, February 12, 2001; 161(3): 353 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Henderson, J. A. Danks, J. M. Moseley, J. L. Slavin, T. L. Harris, M. R. McKinlay, J. L. Hopper, and T. J. Martin Parathyroid Hormone-Related Protein Production by Breast Cancers, Improved Survival, and Reduced Bone Metastases J Natl Cancer Inst, February 7, 2001; 93(3): 234 - 237. [Full Text] [PDF]
|
|
|
|
|
|
T. Michigami, M. Ihara-Watanabe, M. Yamazaki, and K. Ozono Receptor Activator of Nuclear Factor {{kappa}}B Ligand (RANKL) Is a Key Molecule of Osteoclast Formation for Bone Metastasis in a Newly Developed Model of Human Neuroblastoma Cancer Res., February 1, 2001; 61(4): 1637 - 1644. [Abstract] [Full Text]
|
|
|
|
|
|
T. Saarto, C. Blomqvist, P. Virkkunen, and I. Elomaa Adjuvant Clodronate Treatment Does Not Reduce the Frequency of Skeletal Metastases in Node-Positive Breast Cancer Patients: 5-Year Results of a Randomized Controlled Trial J. Clin. Oncol., January 1, 2001; 19(1): 10 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. El Abdaimi, N. Dion, V. Papavasiliou, P.-E. Cardinal, L. Binderup, D. Goltzman, L.-G. Ste-Marie, and R. Kremer The Vitamin D Analogue EB 1089 Prevents Skeletal Metastasis and Prolongs Survival Time in Nude Mice Transplanted with Human Breast Cancer Cells Cancer Res., August 1, 2000; 60(16): 4412 - 4418. [Abstract] [Full Text]
|
|
|
|
|
|
V. Kunzmann, E. Bauer, J. Feurle, F. W.{b.}i. H.-P. Tony, and M. Wilhelm Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Blood, July 15, 2000; 96(2): 384 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Boissier, M. Ferreras, O. Peyruchaud, S. Magnetto, F. H. Ebetino, M. Colombel, P. Delmas, J.-M. Delaisse, and P. Clezardin Bisphosphonates Inhibit Breast and Prostate Carcinoma Cell Invasion, an Early Event in the Formation of Bone Metastases Cancer Res., June 1, 2000; 60(11): 2949 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schirrmeister, A. Guhlmann, J. Kotzerke, C. Santjohanser, T. Kuhn, R. Kreienberg, P. Messer, K. Nussle, K. Elsner, G. Glatting, et al. Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission Tomography J. Clin. Oncol., August 1, 1999; 17(8): 2381 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Dallas, I. R. Garrett, B. O. Oyajobi, M. R. Dallas, B. F. Boyce, F. Bauss, J. Radl, and G. R. Mundy Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease Blood, March 1, 1999; 93(5): 1697 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Diel, E.-F. Solomayer, S. D. Costa, C. Gollan, R. Goerner, D. Wallwiener, M. Kaufmann, and G. Bastert Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment N. Engl. J. Med., August 6, 1998; 339(6): 357 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Mundy and T. Yoneda Bisphosphonates as Anticancer Drugs N. Engl. J. Med., August 6, 1998; 339(6): 398 - 400. [Full Text]
|
|
|
|
 |
|
 T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]
|
|
|
|
|
|
H. Fleisch Bisphosphonates: Mechanisms of Action Endocr. Rev., February 1, 1998; 19(1): 80 - 100. [Abstract] [Full Text]
|
|
|
|
|
|
P. D. Delmas Bisphosphonates in the Treatment of Bone Diseases N. Engl. J. Med., December 12, 1996; 335(24): 1836 - 1837. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
